Full-Length Plasmid Sequencing & Verification

Full-Length Plasmid Sequencing & Verification

Sequence verification of starting materials for lentiviral (transfer / packaging / envelope) and AAV (cis / rep-cap / helper) production plasmids: a single long read from Nanopore or PacBio platforms spans the entire plasmid, confirming the correctness of the target sequence and functional elements, while detecting point mutations, insertions and deletions, rearrangements, and sequence heterogeneity. The service delivers traceable sequence evidence to support plasmid release prior to virus production and to qualify plasmid bank establishment.

1. Background

Viral vectors are not generated de novo; they are produced by transient transfection of packaging cells with plasmids, which therefore constitute the most upstream starting material of the viral vector. In the lentivirus (LVV) system, the sequence of the transfer plasmid—carrying cis-acting elements such as LTR, Ψ, RRE, and WPRE—is transcribed into the vector RNA and packaged into particles, effectively serving as the “master template” for the final packaged RNA. The packaging plasmids (gag-pol, rev) and the envelope plasmid (VSV-G) determine production consistency and the risk of replication-competent lentivirus (RCL). In the AAV system, the sequence between the two ITRs on the cis (vector) plasmid is encapsidated, the rep-cap plasmid defines the serotype, and the helper plasmid provides adenoviral helper functions.

During amplification and serial passaging of plasmids in Escherichia coli, point mutations may accumulate and recombination or deletion events may occur—particularly in repetitive sequences and regions with strong secondary structure. A plasmid that “grows out” is not necessarily one whose sequence is still correct. Once an error is introduced at the source, it is directly inherited by the RNA / DNA of the downstream vector upon transfection, and no amount of downstream characterization can correct an upstream defect. Sanger sequencing performed in segments tends to leave blind spots and ambiguities in repetitive or strongly structured regions and is poorly suited to detecting large structural rearrangements; restriction mapping reflects only the gross architecture. To answer with certainty whether the full-length sequence matches the design exactly—and, if not, where it has changed—single-molecule full-length reads are required. Performing full-length sequence verification at the plasmid stage establishes a quality gate at the most upstream point of the workflow.

Figure 2. Schematic illustration of how plasmid sequence integrity propagates to the viral vector (source → product).

From a regulatory and industry perspective, sequence verification of plasmids as starting materials / expression constructs is supported by clearly established guidance: ICH Q5B (Analysis of the Expression Construct and Genetic Stability), Q6B (Specifications), and Q2(R2) (Method Validation); the FDA’s Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy INDs (2020), which controls production plasmids as starting materials / critical reagents; and the Center for Drug Evaluation (CDE) of China’s NMPA Technical Guideline for Pharmaceutical Research and Evaluation of In Vivo Gene Therapy Products (Trial) (2022), which requires that the sequence correctness, critical quality attributes, and control strategy of starting materials (including plasmids) be clearly defined. This service provides CQA-level data support aligned with these directives.

2. Technical Principle

The service is built around long-read single-molecule sequencing (Nanopore / PacBio), using the customer-supplied full plasmid sequence / map as a custom reference for per-read alignment and full-length verification. The technical characteristics of long-read sequencing map precisely onto the requirements of plasmid verification—full-length coverage, freedom from ambiguity, and clear visibility into structure: single-molecule long reads traverse the entire plasmid in one stretch, making rearrangements, large insertions and deletions, and tandem duplications—events that short reads struggle to assemble—directly observable; long reads preserve the true connectivity between regions, eliminating ambiguities introduced by short-read assembly. The core workflow is as follows:

(1) Sample Receipt and QC

Plasmid DNA is received and assessed for concentration, purity, and preliminary integrity (including supercoiled topology) to confirm suitability for library construction.

(2) Long-Read Library Construction

Longread libraries are prepared on the Nanopore or PacBio platform, with linearization or fragmentation strategies applied as needed to ensure uniform full-length coverage.

(3) Long-Read Sequencing

Sequencing is performed on the Nanopore or PacBio platform to the targeted depth; depth can be increased on demand to support detection of low-frequency variants and sequence heterogeneity.

(4) Bioinformatics Analysis and Sequence Interpretation

Fulllength alignment is performed against the customer plasmid sequence as a custom reference, resolving and locating SNVs, indels, structural rearrangements, and sequence heterogeneity on a per-read basis. Functional elements and the backbone are verified, and a sequence-verification report is issued.

Figure 1. Workflow of full-length plasmid sequencing and sequence verification.

3. Technical Features and Advantages

(1) Single reads spanning the entire plasmid

Single-molecule long reads traverse the full plasmid in one stretch, directly revealing structural events such as rearrangements, large deletions / insertions, and tandem repeats, and addressing the blind spots and ambiguities of segmented Sanger sequencing in repetitive or strongly structured regions.

(2) Unambiguous connectivity

Long reads preserve the true order of region-to-region connectivity (i.e., which segment joins which), avoiding the ambiguities introduced by short-read assembly and reliably answering whether the full-length sequence matches the design and where any deviations occur.

(3) Complementary dual-platform strategy

PacBio HiFi provides high per-base accuracy and is well suited to detecting point mutations and low-frequency heterogeneity; Nanopore provides ultra-long reads and rapid turnaround, well suited to structural and rearrangement screening as well as plasmid-bank qualification. The two platforms can be used independently or in an orthogonal combination for mutual cross-validation.

(4) Customer-designed reference for tailored alignment

Alignment is performed against the customer-supplied full plasmid sequence / map as a custom reference, with every deviation from the design reference reported—delivering quantifiable, position-resolved, and comparable conclusions.

(5) Detection of sequence heterogeneity

Within-population inconsistencies can be identified, indicating instability during passaging or mixed clones, supporting decisions on whether re-cloning and locking of the plasmid bank are warranted.

4. Application Scenarios

Plasmid bank qualification: Serves as the sequence baseline for the master / working plasmid bank (MCB / WCB), supporting bank release and cross-batch comparison.

Verification after construct optimization: Confirms sequence correctness following vector design or construct optimization, informing re-cloning or construct correction.

Pre-production plasmid release: Completes plasmid sequence verification prior to virus production, preventing upstream errors from being carried into costly downstream processes.

Process / supplier change comparison: Performs sequence consistency comparisons before and after process or supplier changes, supporting change assessment.

IND / BLA starting-material characterization: Provides sequence-verification and consistency evidence for plasmid starting materials in regulatory submissions.

5. Report and Deliverables

The report provides quantifiable, position-resolved, and comparable sequence evidence rather than a single pass/fail conclusion. Core content includes:

·Full-length sequence-verification conclusion: overall concordance of the plasmid with the design reference, including coverage.

·Variant list: per-position enumeration of SNVs / indels / structural rearrangements, with position, type, and—where applicable—abundance or heterogeneity fraction.

·Functional-element verification: presence and correctness of key elements including the expression cassette, promoter, polyA, LTR / Ψ / RRE / WPRE or ITR, antibiotic-resistance marker, and origin of replication.

·Sequence-heterogeneity indication: whether within-population inconsistencies exist (suggestive of passaging instability or mixed clones).

·Backbone and exogenous-sequence indications (optional): signals of unintended insertions or out-of-vector sequences.

·Actionable recommendations: directional guidance such as re-cloning, construct correction, or locking the plasmid bank, based on observed deviations.

·Data deliverables: complete analysis report (PDF), sequence-alignment / variant data files, and raw sequencing data.

6. Service Workflow

* Turnaround time: [insert typical turnaround time].

7. Sample Requirements

* The latest Sample Submission Guide takes precedence. This service is not applicable to severely degraded samples. Please contact us in advance to confirm the scheme prior to shipment.

8. Technical Parameters

9. References

[1] ICH. Q5B: Quality of Biotechnological Products — Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products.

[2] ICH. Q6B: Specifications — Test Procedures and Acceptance Criteria for Biotechnological / Biological Products.

[3] ICH. Q2(R2): Validation of Analytical Procedures.

[4] U.S. Food and Drug Administration. Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs); Guidance for Industry, 2020.

[5] Center for Drug Evaluation (CDE), National Medical Products Administration of China. Technical Guideline for Pharmaceutical Research and Evaluation of In Vivo Gene Therapy Products (Trial). 2022. [in Chinese]